查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1133250

白血病治疗药的全球市场:各治疗类型，白血病的各类型，各分子类型 - 各地区展望，竞争策略，各市场区隔预测(～2030年)

Leukemia Therapeutics Market- By Treatment Type, By Type of Leukemia, By Molecule Type - Regional Outlook, Competitive Strategies, and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 208 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球白血病治疗药的市场规模，预计至2030年达到359亿6,000万美元，预计以11.3％的年复合成长率成长。

罹患白血病的人数增加，血液癌症筛检领域的技术改善和突破，牵引全球白血病治疗药市场。再加上预防医疗的重要性相关人们的意识高涨，也预计牵引在预测期间内的市场。

本报告提供全球白血病治疗药市场相关调查，市场动态，市场变数及预测，各治疗类型、白血病的类型、分子类型、地区分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，及课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • COVID-19对全球白血病治疗药市场的影响

第5章 市场变数及预测

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球白血病治疗药市场:各治疗类型，2019年～2030年(100万美元)

  • 化疗
  • 免疫疗法
  • 标靶治疗
  • 其他的治疗方法

第7章 全球白血病治疗药市场:白血病的各类型，2019年～2030年(100万美元)

  • 急性淋巴性白血病
  • 急性骨髓性白血病
  • 慢性淋巴性白血病
  • 慢性骨髓性白血病
  • 其他的白血病类型

第8章 全球白血病治疗药市场:各分子类型，2019年～2030年(100万美元)

  • 低分子化合物
  • 生技药品

第9章 全球白血病治疗药市场:各地区，2019年～2030年(100万美元)

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第10章 企业简介

  • AbbVie Inc.
    • 企业概要
    • 财务预测
    • 产品概要
    • 最近的开发
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company Ltd.
  • Gilead Sciences Inc.
  • iCell Gene therapeutics
  • Merck & Company Inc.
  • Novartis AG
  • Otsuka Holdings Company Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • Stemline Therapeutics Inc.
  • Takeda Pharmaceutical Company Ltd.
简介目录
Product Code: HLCA2210

According to SPER Market Research, the Global Leukemia Therapeutics Market is estimated to reach USD 35.96 billion by 2030 with a CAGR of 11.3%.

Leukemia is a type of blood cancer that affects the bone marrow and lymphatic system. It affects leucocytes, or white blood cells, as the name implies. The DNA of leucocytes is broken in this type of cancer, causing them to proliferate and divide uncontrollably. These cells continue to develop and accumulate, preventing healthy white blood cells from forming and functioning.

Leukemia can be acute or chronic, affecting both red blood cells and platelets. Fever, night sweats, weight loss, an enlarged liver, frequent infections, and swollen lymph nodes are all common symptoms of leukemia. Some of the numerous kinds of leukemia are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. Acute myeloid leukemia, also known as acute myelogenous leukemia, is most common in adults.

Because of the increased number of people suffering from leukemia, technical improvements and breakthroughs in the field of blood cancer testing are driving the Global Leukemia Therapeutics Market. Furthermore, rising public awareness about the importance of preventive healthcare is likely to drive the market throughout the forecast period. Government initiatives and policies encouraging cancer awareness are expected to drive market expansion until 2026.

Impact of COVID-19 on the Global Leukemia Therapeutics Market

The risk of infection is low in treating Leukemia during COVID-19 times. Although the mortality rate maybe be higher in patients with leukemia and COVID-19. Furthermore, according to the study "Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicentre Study During the COVID-19 Outbreak," published in Cancer Discovery in June 2021, the risk of severe COVID-19 infection was found to be higher, at around 57 percent, among patients with blood cancers.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2030

Base year considered 2021

Forecast period 2022-2030

Segments covered By Treatment Type, By Type of Leukemia, By Molecule Type

Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company Ltd., Gilead Sciences Inc. ICell Gene therapeutics, Merck & Company Inc., Novartis AG, Otsuka Holdings Company Ltd., Pfizer Inc., Roche HoldingAG, Stemline Therapeutics Inc., Takeda Pharmaceutical Company Ltd.

Global Leukemia Therapeutics Market, By Treatment Type:

Based on the Treatment Type, Global Leukemia Therapeutics Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy, and Other Treatments

Global Leukemia Therapeutics Market, By Type of Leukemia:

Based on the Type of Leukemia, Global Leukemia Therapeutics Market is segmented as; Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Other Type of Leukemias.

Global Leukemia Therapeutics Market, By Molecule Type:

Based on the Molecule Type, Global Leukemia Therapeutics Market is segmented as; Small Molecules and Biologics.

Global Leukemia Therapeutics Market, By Region:

The Asia Pacific emerged as the leading region in the Global Leukemia Therapeutics Market with the maximum market share in 2021.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data Triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity, and Challenges Analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts on the Global Leukemia Therapeutics Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Leukemia Therapeutics Market, By Treatment Type, 2019-2030 (USD Million)

  • 6.1. Chemotherapy
  • 6.2. Immunotherapy
  • 6.3. Targeted Therapy
  • 6.4. Other Treatments

7. Global Leukemia Therapeutics Market, By Type of Leukemia, 2019-2030(USD Million)

  • 7.1. Acute Lymphocytic Leukemia
  • 7.2. Acute Myeloid Leukemia
  • 7.3. Chronic Lymphocytic Leukemia
  • 7.4. Chronic Myeloid Leukemia
  • 7.5. Other Type of Leukemias

8. Global Leukemia Therapeutics Market, By Molecule Type, 2019-2030 (USD Million)

  • 8.1. Small Molecules
  • 8.2. Biologics

9. Global Leukemia Therapeutics Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1 AbbVie Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2 Amgen Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3 Astellas Pharma Inc.
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4 AstraZeneca PLC
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5 Bristol-Myers Squibb Company
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6 Eli Lilly and Company Ltd.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7 Gilead Sciences Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8 iCell Gene therapeutics
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9 Merck & Company Inc.
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10 Novartis AG
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11 Otsuka Holdings Company Ltd.
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12 Pfizer Inc.
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13 Roche Holding AG
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14 Sanofi
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15 Stemline Therapeutics Inc.
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16 Takeda Pharmaceutical Company Ltd.
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments